



Therapeutic Nanomedicine for Cancer

Murali M Yallapu

University of Texas Rio Grande Valley, USA.

Abstract:

The United States Food and Drug Administration have permitted number of therapeutic agents for cancer treatment. Most of them have some degree of systemic toxicity which makes overbearing in clinical settings. Additionally, drug resistance, metastasis, and recurrence remain to be inexplicable in cancer therapeutics. Urgent and unmet clinical need to deploy successful delivery Nanomedicine of the approved chemotherapy agents precisely to tumors for the effective management of cancer therapy. This talk provides distinct biological and physiological characteristics of such nanomedicine. This talk will also outline specific targeted molecular mechanism(s) of nanomedicine that are responsible for enhanced anti-cancer, anti-metastasis, anti-angiogenesis, and chemo-/radiation sensitizer actions. At the end, it will be covered most recent development, proof, and applications of various nanomedicines and its effective translational approaches.

Biography:

Murali M Yallapu is currently working as Associate Professor (Tenured) in the department of Microbiology and Immunology in University of Texas Rio Grande Valley USA.



Publication of speakers:

1. Curcumin nanoformulations: a future nanomedicine for cancer; MM Yallapu, M Jaggi, SC Chauhan.
2. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells; MM Yallapu, BK Gupta, M Jaggi, SC Chauhan.
3. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy; MM Yallapu, SF Othman, ET Curtis, BK Gupta, M Jaggi, SC Chauhan.
4. Hydrogel networks as nanoreactors: A novel approach to silver nanoparticles for antibacterial applications; Y Murali Mohan, K Lee, T Premkumar, KE Geckeler.
5. Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells; MM Yallapu, M Jaggi, SC Chauhan.

17TH Nanotechnology and Nanomedicine Congress, June 26, 2020, London, UK

Citation: Murali M Yallapu; Therapeutic Nanomedicine for Cancer, USA; Nano Tech - 2020; June 26, 2020; London, UK.